Vigabatrin/CPP-109 Data to be Presented at College on Problems of Drug Dependence Annual Meeting

 

 

CORAL GABLES, Fla., June 9 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today announced that on Tuesday, June 15th at 5:20pm local time, Charles Gorodetzky, MD, PhD will deliver a presentation entitled "Vigabatrin for the treatment of stimulant dependence" at the College on Problems of Drug Dependence's (CPDD) 72nd Annual Meeting in Scottsdale, Arizona. Dr. Gorodetzky, Catalyst's Chief Medical Officer, will present an overview of nonclinical and clinical data obtained from studies of vigabatrin conducted to date which support its continued development as a treatment for cocaine and methamphetamine addiction. Further, the Company reported that the presentation materials from the conference will be posted on June 15th on the Company's website, www.catalystpharma.com, under "Events and Presentations."
 

About Catalyst Pharmaceutical Partners
 

Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction, epilepsy and neuropathic pain. Catalyst has two products in development, and is currently evaluating the lead product candidate, CPP-109 (vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction, which indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address an unmet medical need. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. Further, Catalyst is in the early stages of developing CPP-115, another GABA aminotransferase inhibitor that could be more potent than vigabatrin but may have reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including epilepsy, drug addiction and neuropathic pain. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to GABA aminotransferase. For more information about the Company, go to www.catalystpharma.com.
 

Source: Catalyst Pharmaceutical Partners, Inc.

CONTACT: Patrick J. McEnany, Catalyst Pharmaceutical, Chief Executive
Officer, +1-305-529-2522, pmcenany@catalystpharma.com; or Melody Carey, Rx
Communications Group, Co-President, +1-917-322-2571, mcarey@rxir.com
 

Web Site: http://www.catalystpharma.com/
 

Posted: June 2010

View comments

Hide
(web1)